BioLineRx (BLRX) to Release Earnings on Tuesday

BioLineRx (NASDAQ:BLRXGet Free Report) will release its earnings data before the market opens on Tuesday, March 26th. Analysts expect BioLineRx to post earnings of ($0.22) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

BioLineRx Price Performance

BLRX stock opened at $1.38 on Monday. The business has a 50 day moving average price of $1.22 and a 200 day moving average price of $1.48. The stock has a market cap of $99.97 million, a price-to-earnings ratio of -1.64 and a beta of 1.40. BioLineRx has a fifty-two week low of $0.76 and a fifty-two week high of $2.53. The company has a quick ratio of 1.86, a current ratio of 1.96 and a debt-to-equity ratio of 0.64.

Institutional Investors Weigh In On BioLineRx

Several large investors have recently modified their holdings of BLRX. Renaissance Technologies LLC boosted its holdings in shares of BioLineRx by 49.1% in the third quarter. Renaissance Technologies LLC now owns 68,222 shares of the biotechnology company’s stock valued at $63,000 after acquiring an additional 22,478 shares during the period. LPL Financial LLC boosted its holdings in shares of BioLineRx by 152.7% in the fourth quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 71,134 shares during the period. Envestnet Asset Management Inc. acquired a new stake in shares of BioLineRx in the first quarter valued at approximately $88,000. Finally, Atria Wealth Solutions Inc. acquired a new stake in shares of BioLineRx in the first quarter valued at approximately $178,000. 2.01% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently weighed in on BLRX. HC Wainwright restated a “buy” rating and set a $21.00 target price on shares of BioLineRx in a research note on Thursday, February 29th. StockNews.com raised BioLineRx to a “sell” rating in a report on Monday, December 4th.

View Our Latest Analysis on BLRX

About BioLineRx

(Get Free Report)

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.

Featured Stories

Earnings History for BioLineRx (NASDAQ:BLRX)

Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.